Total Voting Rights
Download full announcement
For the purposes of DTR5.6.1R of the Transparency Directive, the Company notifies the market of the following:
As of 31 July 2019, the Company’s issued and fully paid share capital consists of 59,416,134 ordinary shares with a nominal value of £0.0025 each (“Ordinary Shares”), with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. The total number of voting rights in the Company is therefore 59,416,134.
The above figure of 59,416,134 should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.
|Renalytix AI plc||www.renalytixai.com|
|James McCullough, CEO||Via Walbrook PR or
Tel: +1 646 397 3970
|Stifel (Nominated Adviser & Joint Broker)||Tel: 020 7710 7600|
Alex Price / Jonathan Senior / Ben Maddison (Investment Banking)
|N+1 Singer (Nominated Adviser & Broker)||Tel: 020 7496 3000|
|Aubrey Powell / James White / George Tzimas (Corporate Finance)
Tom Salvesen / Mia Gardner (Corporate Broking)
|Walbrook PR Limited||Tel: 020 7933 8780
|Mob: 07980 541 893
07584 391 303
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant.
RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.